The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1746
ISSUE 1746
January 19, 2026
Issue 1746
- Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
- Nalmefene Autoinjector (Zurnai) for Reversal of Opioid Overdose
- Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
- Imlunestrant (Inluriyo) for Advanced Breast Cancer
- In Brief: A New Indication for Uzedy
- In Brief: Andexanet alfa (Andexxa) Withdrawn
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
January 19, 2026 (Issue: 1746)
The FDA has approved Tonmya (Tonix), a sublingual
tablet formulation of the skeletal muscle relaxant
cyclobenzaprine, for treatment of fibromyalgia in
adults. Cyclobenzaprine is available in immediate-release
tablets and extended-release capsules...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
